Andrew Hirsch
President & CEO at C4 Therapeutics Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: C4 Therapeutics Inc., 3 years.
C4 Therapeutics Inc.
Director · President & CEO
Editas Medicine Inc.
Director
Chief executive roles
C4 Therapeutics Inc.
· President & CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 15, 2026 | C4 Therapeutics Inc. | Option exercise | +20,400 | — | — |
| Feb 15, 2026 | C4 Therapeutics Inc. | Shares withheld for tax | −9,057 | $1.89 | $17,118 |
| Feb 14, 2026 | C4 Therapeutics Inc. | Option exercise | +81,725 | — | — |
| Feb 14, 2026 | C4 Therapeutics Inc. | Shares withheld for tax | −39,154 | $1.89 | $74,001 |
| Feb 13, 2026 | C4 Therapeutics Inc. | Grant or award | +700,000 | — | — |
| Feb 15, 2025 | C4 Therapeutics Inc. | Shares withheld for tax | −9,370 | $3.18 | $29,797 |
| Feb 14, 2025 | C4 Therapeutics Inc. | Grant or award | +223,500 | — | — |
| Feb 14, 2025 | C4 Therapeutics Inc. | Shares withheld for tax | −12,847 | $3.18 | $40,853 |
| Nov 7, 2024 | C4 Therapeutics Inc. | Option exercise | +12,500 | — | — |
| Nov 7, 2024 | C4 Therapeutics Inc. | Shares withheld for tax | −5,550 | $6.04 | $33,522 |
| Sep 16, 2024 | C4 Therapeutics Inc. | Option exercise | +7,500 | — | — |
| Sep 16, 2024 | C4 Therapeutics Inc. | Shares withheld for tax | −3,329 | $6.36 | $21,172 |
| Feb 15, 2024 | C4 Therapeutics Inc. | Shares withheld for tax | −6,560 | $7.90 | $51,824 |
| Feb 14, 2024 | C4 Therapeutics Inc. | Grant or award | +103,400 | — | — |
| Aug 30, 2023 | C4 Therapeutics Inc. | Option exercise | +7,500 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.